Zomedica White Paper Unveils New Market Opportunities for PulseVet Therapy

Zomedica Corp. (NYSE American: ZOM) has released a white paper presenting the expanded applications of its PulseVet therapy. This report highlights the efficacy of PulseVet in treating Exercise Induced Pulmonary Hemorrhage (EIPH) in quarter horses and suggests it as a non-invasive, drug-free alternative for equine asthma. PulseVet, known for addressing orthopedic issues, shows promise in lung and respiratory treatments.

Dr. Beau Whitaker, author of the study, emphasizes that this energy-based technology may offer benefits in immune pathways critical for equine asthma. The white paper cites significant improvements in horses treated for EIPH, outperforming traditional medications like furosemide. PulseVet's mechanism involves high-energy sound waves to stimulate cellular healing, thus promoting reduced inflammation and enhanced blood flow.

Furthermore, Zomedica estimates a market potential of $1 billion in capital equipment sales and $150 million in annual recurring revenue for PulseVet. Early results in asthma studies are promising, presenting new revenue opportunities. Zomedica remains focused on innovation in veterinary diagnostics and therapeutics, with PulseVet therapy leading their growth strategy.